Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

Shots:

• Chembio to receive funding if reaches certain milestones, to develop POC test utilizing Chembio’s DPP platform and hand-held optical analyzer. The POC test will be built upon Takeda’s biomarker and is expected to provide results in ~15 mins. from a 10µL drop of fingerstick blood
• The collaboration is to combine Chembio’s DPP platform and Takeda’s expertise to develop and commercialize a novel POC diagnostic test to improve patient’s health
• Chembio’s DPP technology utilizes a small drop of blood from the fingertip to detect diseases and is also used for DPP HIV 1/2 Assay which has received the US FDA and ANVISA’s approval, CLIA-waiver, WHO prequalification and CE mark

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Takeda